Jilin Aodong: Announcement on the change of signing project partners and quality control reviewers
Securities code: 000623 Securities abbreviation: Jilin Aodong Announcement number: 2026-002
Jilin Aodong Pharmaceutical Group Co., Ltd.
Announcement on the change of signing project partners and quality control reviewers
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Jilin Aodong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or "Jilin Aodong") held the 18th meeting of the 11th Board of Directors, the 16th meeting of the 11th Board of Supervisors and 2025 on September 19, 2025 respectively. The first extraordinary general meeting of shareholders in 2020 reviewed and approved the "Proposal on Re-appointment of the Accounting Firm" and agreed to re-appoint Beijing Dehao International Accounting Firm (Special General Partnership) (hereinafter referred to as "Dehao Firm") as the company's audit agency for 2025, responsible for the company's 2025 financial audit and internal control audit. For details, please refer to the company's announcements on August 30, 2025 and September 20, 2025 respectively. The "Announcement on Resolutions of the 18th Meeting of the 11th Board of Directors" (public announcement) was disclosed in the "Securities Times", "China Securities News", "Shanghai Securities News", "Securities Daily" and cninfo.com (http://www.cninfo.com.cn). Announcement No.: 2025-038), "Announcement on the Resolutions of the 16th Meeting of the Eleventh Supervisory Board" (Announcement No.: 2025-039), "Announcement on Re-appointment of the Accounting Firm" (Announcement No.: 2025-046) and "2025 Announcement of Resolutions of the First Extraordinary General Meeting of Shareholders of 2020 (Announcement No.: 2025-052).
The company received the "Letter on Changing the 2025 Audit Signature Project Partner and Quality Control Reviewer of Jilin Aodong Pharmaceutical Group Co., Ltd." issued by Dehao Firm on January 28, 2026. The relevant changes are now notified as follows:
1. Basic information on changing signature project partners and quality control reviewers
As the audit agency for the company's 2025 annual audit report and internal control, Dehao Firm originally assigned Hui Qiangqiang as the signing project partner and Cai Bin as the quality control reviewer to provide audit services for the company. Due to the internal work arrangements of Dehao Firm, Zhao Huantong is now assigned to replace Hui Qiangqiang as the signing project partner, and Cong Cun is assigned to replace Cai Bin as the quality control reviewer to continue to complete the company's 2025 audit work.
2. Basic information of the signed project partners and quality control reviewers after the change
1.Basic information
Partner of the project to be signed: Zhao Huantong, who became a Chinese Certified Public Accountant in 2016, began to engage in the audit business of listed companies in 2016, started practicing at Dehao Firm in February 2025, and began to provide audit services for the company in 2025. In the past three years, we have signed the audit reports of two listed companies, Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) and Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SH).
Proposed quality control reviewer: Cong Cun, who became a certified public accountant in June 2010, started auditing listed companies in January 2008, started practicing at Dehao Firm in October 2025, and plans to start providing audit services for the company in 2025. In the past three years, 6 companies have signed audit reports of listed companies, 3 companies have reviewed audit reports of listed companies, 4 companies have signed NEEQ audit reports, and 3 companies have reviewed NEEQ audit reports.
- Independence and integrity
Zhao Huantong has not violated the independence requirements of the "Chinese Code of Professional Ethics for Certified Public Accountants"; in the past three years, she has not been subject to criminal penalties for professional conduct, administrative penalties, supervisory and management measures from the China Securities Regulatory Commission and its dispatched agencies, industry authorities, etc., and self-regulatory measures and disciplinary sanctions from self-regulatory organizations such as stock exchanges and industry associations.
Cong Cun has not violated the independence requirements of the "Chinese Code of Professional Ethics for Certified Public Accountants"; he has not been criminally punished for his professional behavior in the past three years, and has not been subject to administrative penalties by the China Securities Regulatory Commission, local agencies, or industry authorities for his professional behavior. For specific information on the administrative supervision measures taken by the China Securities Regulatory Commission and local agencies due to his professional behavior, please see the table below:
processing office processing office
Serial number Name Implementing unit Reason and punishment
Penalty date Penalty type
Due to the implementation of the 2023 China Securities Regulatory Commission of Beijing Feilixin Technology Co., Ltd.
The 2022 annual report audit was issued by the China Securities Regulatory Commission 1 Cong Cun September 25 Warning Letter Management Committee North
The regulatory committee issued a warning letter from the Beijing Supervision Bureau.
Supervision and management measures
In 2024, due to the implementation of Guilin Guanglong Technology Group Co., Ltd.
Disciplinary Office Shanghai Securities Exchange
2 Congcun issued shares for the first time on December 31 and listed its branch on the Science and Technology Innovation Board
On the same day, the application project was disciplined by the Shanghai Stock Exchange
3. The impact of this change of signing project partners on the company
This change of signing project partners is due to the internal work adjustment of the audit institution, and the relevant work arrangements have been handed over in an orderly manner. The changes will not have an adverse impact on the company's 2025 audit work.
4. Documents for reference
Letter from Beijing Dehao International Accounting Firm (Special General Partnership) on changing the 2025 audit signature project partner and quality control reviewer of Jilin Aodong Pharmaceutical Group Co., Ltd.;
Professional qualification certificates and identity documents of the signed project partners and quality control reviewers after the change; 3. Other documents required by the Shenzhen Stock Exchange.
Announcement is hereby made.
Jilin Aodong Pharmaceutical Group Co., Ltd. Board of Directors
January 31, 2026